Zhengye Biotechnology-AZYBT
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 10 institutions reported holding Zhengye Biotechnology-A (ZYBT) in their 13F filings, up 1 from Q2 2025. 5 opened new positions and 4 sold out. The largest holders were Invesco Ltd. ($96K), XTX Topco Ltd ($91K) and Geode Capital Management, LLC ($76K). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Zhengye Biotechnology-A
- CUSIP
- G989MS101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $216K |
| Exits | 4 | $1.2M |
All 13F filers, Q2 2025 → Q3 2025: 83,550 shares bought and 345,349 shares sold, net −261,799 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Invesco Ltd. | 0.00% | Reduce -1.1% | 36,451 | $96K |
| XTX Topco Ltd | 0.00% | New | 34,589 | $91K |
| Geode Capital Management, LLC | 0.00% | No change | 29,068 | $76K |
| WINTON GROUP Ltd | 0.00% | New | 21,547 | $56K |
| Millennium Management | 0.00% | New | 14,602 | $38K |
| Citadel Advisors | 0.00% | New | 11,685 | $31K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +33.8% | 4,462 | $12K |
| UBS Group AG | 0.00% | Reduce -97.2% | 4,329 | $11K |
| Morgan Stanley | 0.00% | Reduce -17.5% | 2,009 | $5K |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $3 |
"% of holder's portfolio" is ZYBT's weight in each manager's 13F, not the share of Zhengye Biotechnology-A the manager owns.